Price history
¥1,242Latest+32.1%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 20
PER
94.55How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
1.71How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
1.8%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥38bnShare price × number of shares. The value of the entire company.Equity ratio
44.7%The proportion of assets funded by money that does not have to be repaid.Operating margin
2.5%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
11.3%The average annual growth in sales over the past three years.What to watch next
Financial results showing the full-year contribution from プラステンメディカル, consolidated from January 2026, including synergies and integration costs
Second half of FY2026 through the results for the fiscal year ending March 2027Impact MediumLikelihood Medium
Establishment of operations for the medical device sales and logistics platform, including WINHeartGate, and systems investments, centered on software acquisitions in 2026
During FY2026Impact MediumLikelihood Medium
Confirmation of the results of passing through the impact of revisions to medical fees and reimbursement prices for specified insured medical materials, and of solution-based sales, in response to the selling price and demand environment
Linked to the timing of system revisions, with confirmation in the results for the next revision cycleImpact HighLikelihood Medium
Visibility on the continuation of share buybacks and the dividend policy, including the planned ¥54 dividend, and progress toward capital efficiency targets, including ROE above 15%
Disclosure of the FY ending June 2026 and 2027 shareholder-return policiesImpact MediumLikelihood High
What to watch next
Who owns itTop holders total 66.0%
Listed holders 66.0%Everyone else 34.0%
㈲オフィスＡ25.75%
BBF FOR FIDELITY LOW-PRICED STOCK FUND (Mitsubishi UFJ Bank, standing proxy)7.25%
キエマ企画6.88%
秋田裕二6.24%
グリーンホスピタルサプライ㈱5.82%
The Master Trust Bank of Japan (Trust Account)4.26%
Akizawa Hideumi (秋沢英海)3.28%
古川國久2.64%
2 other listed holders3.92%
| Holder | Ownership (%) |
|---|---|
| ㈲オフィスＡ | 25.75 |
| BBF FOR FIDELITY LOW-PRICED STOCK FUND (Mitsubishi UFJ Bank, standing proxy) | 7.25 |
| キエマ企画 | 6.88 |
| 秋田裕二 | 6.24 |
| グリーンホスピタルサプライ㈱ | 5.82 |
| The Master Trust Bank of Japan (Trust Account) | 4.26 |
| Akizawa Hideumi (秋沢英海) | 3.28 |
| 古川國久 | 2.64 |
| 2 other listed holders | 3.92 |
This company's documents
Filings
Timely disclosures
- 2026-08-04Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
- 2026-06-25Corporate Governance Report 2026/06/25
- 2026-06-02Notice of Convocation of the 13th Annual General Meeting of Shareholders in 2026 (Matters Omitted from the Documents Delivered)
- 2026-06-02Notice of Convocation of the 13th Annual General Meeting of Shareholders for 2026
- 2026-05-15Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP) (Consolidated)
- 2026-04-01Notice Regarding the Status of Share Repurchases and Completion of the Repurchase Program
- 2026-03-10Notice Regarding the Status of Share Repurchases